<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2203233409
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SEVORANE INHAL.ANESTHESIA Plastic BOTTLE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SEVOFLURANE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Inhalation vapour, liquid
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        514.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AESICA QUEENBOROUGH LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AESICA QUEENBOROUGH LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 392]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-KAMAL IMPORT OFFICE CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbvie Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N01AB08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sevorane (Sevoflurane) belongs to a group of medicines called general anaesthetics. These work by temporarily reducing the activity of the body&rsquo;s central nervous system. This causes a complete loss of sensation in the body, including loss of consciousness allowing surgery to be carried out without pain or distress.</p><p>Sevorane is a clear colourless liquid, that when put into a special anaesthetic machine (vaporiser) becomes a gas. This mixes with the oxygen you will be breathing in.</p><p>Once breathed in (inhaled), Sevorane will induce and maintain a deep, pain-free sleep (general anaesthesia) in adults and children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>TELL YOUR WARD DOCTOR, SURGEON OR ANAESTHETIST if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have been told previously that you should not receive general anaesthesia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have been told that you are sensitive or have an allergy to Sevorane or any other anaesthetic.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You or any member of your family has had a condition called malignant hyperthermia (rapid increase in body temperature and severe muscle contractions) during an operation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have liver problems or if you have previously had general anaesthetics, particularly if repeated over a short period of time. Some anaesthetics can occasionally cause problems in the liver, which can cause yellowing of the skin and eyes (jaundice).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are prone to or at risk for seizures (fits).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have ever had QT prolongation (prolongation of a specific time interval in an ECG) or torsade de pointes (a specific type of heart rhythm), which may also be associated with QT prolongation. Sevorane has sometimes been known to cause these.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a mitochondrial disease.</p><p>&nbsp;</p><p>In addition to the above, if Sevorane is to be administered to your child, please tell their ward doctor, surgeon or anaesthetist if they:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have seizures or seizure disorder (fits), as Sevorane may increase the risk of seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have Pompe&rsquo;s disease (a metabolic disorder). Sevorane may produce abnormal heart rhythms, which may be severe in some cases</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a severe muscle disorder such as Duchenne muscular dystrophy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a mitochondrial disorder, which is a disorder that people may be born with and may affect special cells of the heart, brain, and kidney.</p><p>&nbsp;</p><p>&nbsp;</p><p>As with all drugs, it is important that you tell your ward doctor or anaesthetist which medications you are taking. This is particularly important if you are taking the following drugs:</p><p>&nbsp;</p><p>&middot;&nbsp; Amphetamines (stimulants)</p><p>&middot;&nbsp; Beta blockers, calcium antagonists or a drug called verapamil (used to treat high blood pressure and certain heart conditions)</p><p>&middot;&nbsp; Isoniazid (an antibiotic used to treat tuberculosis)</p><p>&middot;&nbsp; St John&rsquo;s Wort (a herbal remedy used to help with depression)</p><p>&middot;&nbsp; Decongestants (ephedrine).</p><p>&middot;&nbsp; Non-selective monoamine oxidase (MAO) inhibitors (a type of antidepressants)</p><p>&middot;&nbsp; Calcium antagonists</p><p>&middot;&nbsp; Benzodiazepines and Opioids</p><p>&middot;&nbsp; Sympathomimetic agents such as isoprenaline</p><p>&nbsp;</p><p><strong>PREGNANCY AND BREAST FEEDING</strong></p><p>Tell your ward doctor, surgeon or anaesthetist if you are pregnant, could be pregnant or are breast feeding. It is not known whether Sevorane or its by-products are transferred into human milk. It is advisable to stop breast-feeding for 48 hours after Sevorane administration and discard any milk that is produced during this period.</p><p>&nbsp;</p><p><strong>DRIVING &amp; USING MACHINERY</strong></p><p>You should <strong>NOT </strong>drive or operate machinery after your operation or procedure, for which the</p><p>anaesthetic has been administered, until your ward doctor advises that you may do so.</p><p>Your ability to drive or operate machinery may be impaired for some time.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sevorane will <strong>ALWAYS </strong>be administered to you by an anaesthetist. They will decide on the dose you will receive, depending on your age, weight and the type of operation you are having. Sevorane will send you to sleep quickly and smoothly. It also has a pleasant smell.</p><p><strong>Inducing sleep at the start of anaesthesia</strong></p><p>To send you to sleep, you may be asked to breathe in Sevorane through a mask. However on most occasions you will be given an injection of another anaesthetic to make you go to sleep before receiving Sevorane.</p><p>&nbsp;</p><p><strong>Maintaining sleep during anaesthesia</strong></p><p>Under the observation of the anaesthetist you will continue to breathe in Sevorane during the</p><p>operation via a mask.</p><p><strong>Waking-up after anaesthesia</strong></p><p>Once the anaesthetist stops you from inhaling Sevorane you will wake up within a few minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>As with all anaesthetics, Sevorane can cause side effects.<br />These can occur both <strong>during </strong>and <strong>after </strong>your operation.</p><p>&nbsp;</p><p><strong>The frequency of side effects is classified as follows:</strong></p><p><strong>Very common: </strong>more than 1 out of 10 persons treated;</p><p><strong>Common: </strong>less than 1 out of 10, but more than 1 out of 100 persons treated; <strong>Uncommon: </strong>less than 1 out of 100, but more than 1 out of 1,000 persons treated; <strong>Rare: </strong>less than 1 out of 1,000, but more than 1 out of 10,000 persons treated. <strong>Very rare: </strong>less than 1 out of 10,000 persons treated.</p><p><strong>Unknown: </strong>when an estimation of frequency is not possible.</p><p>&nbsp;</p><p>The following side effects with Sevorane are serious and will be managed by your surgeon or anesthetist, as necessary, during the operation. If you experience any of these side effects after your operation <strong>get medical help immediately.</strong></p><p><strong>Those occurring with unknown frequency:</strong></p><p>&middot;&nbsp; Allergic reactions with symptoms such as rash, swelling of the face, wheezing</p><p>&middot;&nbsp; Rapid rise in body temperature (malignant hyperthermia)</p><p>&middot;&nbsp; Wheezing and breathlessness</p><p><strong>Those occurring very commonly:</strong></p><p>&middot;&nbsp; Slow heart rate (bradycardia)</p><p><strong>Those occurring commonly</strong></p><p>&middot;&nbsp; Throat spasm</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Those occurring uncommonly</strong></p><p>&middot;&nbsp; Heart disorders (AV block), which will be closely monitored by your anesthetist during your operation and may be recognized by dizziness after your operation</p><p>The frequency of other side effects observed following the use of Sevoflurane are:</p><p><strong>Very common frequency:</strong></p><p>&middot;&nbsp; agitation</p><p>&middot;&nbsp; decreased blood pressure (hypotension)</p><p>&middot;&nbsp; cough</p><p>&middot;&nbsp; nausea</p><p>&middot;&nbsp; vomiting</p><p>&nbsp;</p><p><strong>Common frequency:</strong></p><p>&middot;&nbsp; drowsiness (somnolence)</p><p>&middot;&nbsp; dizziness</p><p>&middot;&nbsp; increased blood pressure (hypertension)</p><p>&middot;&nbsp; headache</p><p>&middot;&nbsp; fast heart rate (tachycardia)</p><p>&middot;&nbsp; slow shallow breathing (respiratory depression)</p><p>&middot;&nbsp; watering mouth (salivary hypersecretion)</p><p>&middot;&nbsp; chills</p><p>&middot;&nbsp; fever (pyrexia)</p><p>&middot;&nbsp; low body temperature (hypothermia)</p><p>&middot;&nbsp; abnormal sugar (glucose) level</p><p>&middot;&nbsp; abnormal liver function test*</p><p>&middot;&nbsp; white blood cell count abnormal</p><p>&middot;&nbsp; blood fluoride increased **</p><p>&middot;&nbsp; delirium</p><p><strong>Uncommon frequency:</strong></p><p>&middot;&nbsp; a decrease or increase in the number of certain white blood cells. A decrease in the number of white blood cells may be associated with dizziness, fatigue, weakness, mouth ulcers and a tendency towards infections.</p><p>&middot;&nbsp; confusion</p><p>&middot;&nbsp; abnormal heart rhythm</p><p>&middot;&nbsp; pauses in breathing</p><p>&middot;&nbsp; inadequate amount of oxygen</p><p>&middot;&nbsp; asthma</p><p>&middot;&nbsp; difficulty in passing urine</p><p>&middot;&nbsp; glucose in the urine***</p><p>&middot;&nbsp; abnormal kidney function test*</p><p>&nbsp;</p><p><strong>Unknown frequency:</strong></p><p>&middot;&nbsp; convulsions (fits), particularly in children</p><p>&middot;&nbsp; twitching and jerking movements</p><p>&middot;&nbsp; fluid in the lungs</p><p>&middot;&nbsp;&nbsp;&nbsp; inflammation or damage to the liver. People with liver disease may have abdominal pain or fullness, dark urine, pale or white-coloured stool, fatigue, general itching, yellowing of the eyes, nausea and vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp; Kidney failure. People with kidney disease may have tiredness, swelling or puffiness in the face, abdomen, thighs or ankles, passing less urine or problems urinating and back pain</p><p>&middot;&nbsp;&nbsp;&nbsp; skin rashes</p><p>&middot;&nbsp;&nbsp;&nbsp; heart arrhythmia (irregular heartbeat or abnormal heart rhythm) known as QT prolongation</p><p>*If you have a blood test, you may be told that you have changes in your liver or kidney enzymes or other products found in the blood. These will not normally cause any symptoms.</p><p>**Levels of fluoride in the blood may be raised slightly during and immediately after anesthesia, due to the body breaking down Sevorane, but these levels are not believed to be harmful and soon return to normal.</p><p>*** If you have a urine test you may be told that you have glucose in your urine. You may not have any symptoms.</p><p>There have been very rare reports of cardiac arrest, a condition where the heart stops beating.</p><p>After surgery, some children may have irregular heart rhythms, which can potentially be life-threatening, due to changes in blood potassium levels.</p><p>Children with Pompe&rsquo;s disease, a disease that they are born with, may have irregular heart rhythm during anesthesia with Sevoflurane.</p><p><strong>After receiving Sevorane</strong></p><p>You will come round or wake up within a few minutes. Children in particular, may be restless on</p><p>awakening. Tell your doctor or anaesthetist if you need additional pain relief.</p><p>If you have any other unusual or unexpected symptoms after receiving Sevoflurane anaesthesia, tell</p><p>your ward doctor or anaesthetist immediately.</p><p>If you have any questions about Sevorane which are not answered by this leaflet, ask your ward</p><p>doctor or anaesthetist.</p><p>&nbsp;</p><p><strong>Reporting side effects</strong></p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this</p><p>leaflet. You can also report side effects directly (see details below). By reporting side affects you can</p><p>help provide more information on the safety of this medicine.</p><p>To report any side effect(s):</p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>Fax: +966-11-205-7662</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p><strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sevorane should be stored in a tightly closed container</p><p>Store below 30<sup>&deg;</sup>C. Do not refrigerate</p><p>Do not use after the expiry date printed on the packaging.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Sevorane ingredients:</strong></p><p>The active ingredient is Sevorane. Water is also present to provide the Sevorane with</p><p>protection from substances that can cause its breakdown (environmental Lewis acids).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                -
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>AbbVie Ltd</p><p>Maidenhead,</p><p>United Kingdom</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>AbbVie S.r.l.</p><p>04011 Campoverde di Aprilia (LT)</p><p>Italy</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last updated in March 2018.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي سيفورين (سيفوفلوران) إلى مجموعة الأدوية التي تسمى أدوية التخدير العام. تعمل هذه الأدوية عن طريق الإنقاص المؤقت لفعالية الجهاز العصبي المركزي في الجسم. يؤدي هذا إلى فقد الإحساس تماما في الجسم، ويتضمن الغياب عن الوعي مما يسمح بإجراء الجراحة دون ألم أو ضيق.</p><p dir="RTL">سيفورين سائل رائق (صاف) عديم اللون، يتحول إلى غاز عند وضعه في آلة تخدير خاصة (مبخرة). ويمتزج هذا الغاز بالأكسجين الذي ستستنشقه.</p><p dir="RTL">بمجرد استنشاقه، سيؤدي إلى إحداث نوم عميق لا ألم فيه (تخدير عام) والمحافظة عليه لدى البالغين والأطفال.&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أخبر طبيبك في الجناح، طبيبك الجراح أو طبيب التخدير إذا</strong><strong>:</strong></p><p dir="RTL">&middot; سبق أن أُخبرت بوجوب الامتناع عن تلقي تخدير عام.</p><p dir="RTL">&middot; سبق أن أُخبرت بأنك حساس أو لديك حساسية تجاه سيفورينن أو أي دواء مخدّر آخر.</p><p dir="RTL">&middot; إذا أصبت أنت أو أحد أفراد أسرتك بحالة تدعى ارتفاع الحرارة الخبيث (ارتفاع سريع في درجة حرارة الجسم وتقلصات عضلية شديدة) أثناء عمل جراحي.</p><p dir="RTL">&middot; إذا كنت تعاني من مشاكل كبدية أو كنت قد تلقيت في السابق مخدرا عاما، وخاصة إذا تكرر هذا خلال فترة زمنية قصيرة. يمكن لبعض أدوية التخدير أن تسبب أحيانا مشاكل في الكبد، وهذا قد يسبب اصفرار الجلد والعينين (يرقان).</p><p dir="RTL">&middot; إذا كنت معرّضا للإصابة بالنوبات.</p><p dir="RTL">&middot; إذا سبق أن أصبت بتطاول فاصلة QT (تطاول فاصلة زمنية معينة في مخطط القلب الكهربائي) أو بنظم Torsade de pointes (نظم قلبي خاص)، الذي قد يترافق أيضا بتطاول فاصلة QT. عُرف عن سيفورين أنه يحدث هذه الاضطرابات.</p><p dir="RTL">&middot; عندما تكون مصابا بمرض ميتوكوندري.</p><p dir="RTL">بالإضافة إلى ما ذكر أعلاه، إذا كان سيفورين سيعطى لطفلك، فالرجاء أن تبلغ طبيبه في الجناح، طبيبه الجراح أو طبيب التخدير إذا كان طفلك:</p><p dir="RTL">&middot; مصابًا بالنوبات أو اضطرابات النوبات، لأن سيفورين قد يزيد من إمكانية الإصابة بالنوبات.</p><p dir="RTL">&middot; مصابًا بمرض بومبي (Pompe) (اضطراب استقلابي). قد يسبب سيفورين اضطرابا في نظم القلب، وقد يكون شديدا في بعض الحالات.</p><p dir="RTL">&middot; مصابًا باضطراب عضلي شديد مثل حثل دوشن (Duchenne) العضلي</p><p dir="RTL">&middot; مصابًا باضطراب ميتوكوندري، وهو اضطراب قد يولد الأطفال وهم مصابون به وقد يؤثر على خلايا معينة في القلب، الدماغ، والكلية.</p><p>&nbsp;</p><p dir="RTL">كما هي الحال مع كافة الأدوية، من المهم أن تخبر طبيبك في الجناح أو طبيب التخدير ما هي الأدوية التي تتناولها. وهذا الأمر هام بشكل خاص إذا كنت تتناول الادوية التالية:&nbsp;</p><p dir="RTL">&middot; أدوية الأمفيتامين (منبهات)</p><p dir="RTL">&middot; حاصرات بيتا، مضادّات الكالسيوم أو دواء يدعى فيراباميل (ويستعمل لعلاج ضغط الدم المرتفع وبعض الحالات القلبية)</p><p dir="RTL">&middot; إيزونيازيد (مضاد حيويي يستعمل لعلاج السلّ)</p><p dir="RTL">&middot; عشبة سات جون (علاج عشبي يستعمل للمساعدة في حالات الاكتئاب)</p><p dir="RTL">&middot; مضادات الاحتقان (إفدرين).</p><p dir="RTL">&middot; مثبطات مونو أمين أكسيداز غير الانتقائية (نوع من مضادات الاكتئاب)</p><p dir="RTL">&middot; مضادّات الكالسيوم.</p><p dir="RTL">&middot; أدوية البنزوديازبين والأدوية أفيونية المفعول.</p><p dir="RTL">&middot; العوامل المقلدة للودّي مثل إيزوبرنالين.</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">أخبري طبيبك في الجناح، طبيبك الجراح أو طبيب التخدير إذا كنتِ حاملا، أو قد تكونين حاملا أو إذا كنت ترضعين. لا يُعرف إذا كان سيفورين أو أحد نواتج استقلابه ينتقل إلى حليب الثدي عند الإنسان. يُنصح بالتوقف عن الإرضاع لمدة ٤٨ ساعة بعد إعطاء سيفورين والتخلص من أي حليب يُنتج خلال هذه الفترة.</p><p dir="RTL"><strong>القيادة واستعمال الآليات</strong></p><p dir="RTL">يجب أن<strong> تمتنع </strong>عن القيادة أو تشغيل الآليات بعد العملية أو الإجراء الذي خضعت له والذي أعطيت الدواء المخدر من أجله، إلى أن يشير عليك طبيبك في الجناح بإمكانية قيامك بها.</p><p dir="RTL">قد تتعطل قدرتك على القيادة أو تشغيل الآليات لبعض الوقت.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيعطى سيفورين لك <strong>دوما</strong> من قبل طبيب مختص بالتخدير. وهو الذي سيقرر الجرعة التي ستتلقاها، حسب عمرك، وزنك ونوع العمل الجراحي الذي ستخضع له. سيجعلك سيفورين تنام بسرعة وهدوء. وهو يتمتع برائحة لطيفة أيضا.</p><p dir="RTL"><strong>إحداث النوم عند بدء التخدير</strong></p><p dir="RTL">لكي تصل إلى النوم، قد يطلب منك أن تستنشق سيفورين عن طريق قناع. ولكن في معظم الحالات، ستعطى حقنة من دواء مخدّر آخر تجعلك تنام قبل أن تتلقى سيفورين.</p><p dir="RTL"><strong>الحفاظ على النوم أثناء التخدير</strong></p><p dir="RTL">ستستمر باستنشاق سيفورين أثناء العمل الجراحي عبر القناع تحت إشراف طبيب التخدير.</p><p dir="RTL"><strong>الاستيقاظ بعد التخدير</strong></p><p dir="RTL">بمجرد أن يوقفك طبيب التخدير عن استنشاق سيفورين، ستستيقظ خلال بضع دقائق.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هي الحال مع كافة أدوية التخدير، من الممكن أن يسبب سيفورين تأثيرات جانبية.</p><p dir="RTL">قد تحدث هذه التأثيرات الجانبية <strong>أثناء</strong> العمل الجراحي و<strong>بعده</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يصنّف معدّل حدوث التأثيرت الجانبية كما يلي:</p><p dir="RTL">شائعة جدا: أكثر من ١ من كل ١٠ أشخاص تلقوا العلاج؛</p><p dir="RTL">شائعة: أقل من ١ من كل ١٠ أشخاص، ولكن أكثر من ١ من كل ١٠٠ شخص تلقى العلاج؛</p><p dir="RTL">غير شائعة: أقل من ١ من كل ١٠٠، ولكن أكثر من ١ من كل ١٠٠٠ شخص تلقى العلاج؛</p><p dir="RTL">نادرة: أقل من ١ من كل ١٠٠٠، ولكن أكثر من ١ من كل ١٠٫٠٠٠ شخص تلقى العلاج؛</p><p dir="RTL">نادرة جدا: أقل من ١ من كل ١٠٫٠٠٠ شخص تلقى العلاج.</p><p dir="RTL">معدل الحدوث غير معروف: عندما يكون تقدير معدّل الحدوث غير ممكن.</p><p>&nbsp;</p><p dir="RTL">التأثيرات الجانبية التالية التي تحدث بسبب سيفورين خطيرة وسيتم تدبيرها من قبل الجراح أو طبيب التخدير، أثناء العمل الجراحي.&nbsp; إذا عانيت من أي من هذه التأثيرات الجانبية بعد العمل الجراحي <strong>فاطلب مساعدة طبية على الفور.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التأثيرات ذات معدل الحدوث غير المعروف:</strong></p><p dir="RTL">&middot; تفاعلات تحسسية مترافقة بأعراض مثل الطفح، تورّم الوجه، أزيز</p><p dir="RTL">&middot; ارتفاع سريع في درجة حرارة الجسم (ارتفاع الحرارة الخبيث)</p><p dir="RTL">&middot; أزيز وانقطاع النفس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية التي تحدث بمعدل شائع جدا:</strong></p><p dir="RTL">&middot; بطء ضربات القلب (بطء القلب)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية التي تحدث بمعدل شائع:</strong></p><p dir="RTL">&middot; تشنج الحلق</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التأثيرات الجانبية التي تحدث بمعدل غير شائع:</strong></p><p dir="RTL">&middot; اضطرابات القلب (إحصار أذيني بطيني)، والتي ستراقب بدقة من قبل طبيب التخدير أثناء العمل الجراحي ومن</p><p dir="RTL">الممكن التعرف إليه بسبب الدوخة الحادثة بعد انتهاء العمل الجراحي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن معدل حدوث التأثيرات الجانبية الملاحظة بعد استعمال سيفوفلوران هو:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>معدل حدوث شائع جدا:</strong></p><p dir="RTL">&middot; نرفزة</p><p dir="RTL">&middot; انخفاض ضغط الدم (هبوط الضغط)</p><p dir="RTL">&middot; سعال</p><p dir="RTL">&middot; غثيان</p><p dir="RTL">&middot; تقيؤ</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>معدل حدوث شائع:</strong></p><p dir="RTL">&middot; نعاس (نيمومة)</p><p dir="RTL">&middot; الدوخة</p><p dir="RTL">&middot; ارتفاع ضغط الدم</p><p dir="RTL">&middot; صداع</p><p dir="RTL">&middot; ضربات قلب سريعة (تسرّع القلب)</p><p dir="RTL">&middot; تنفس سطحي بطيء (ضيق تنفسي)</p><p dir="RTL">&middot; سيلان الفم (فرط إفراز اللعاب)</p><p dir="RTL">&middot; نوبات قشعريرة</p><p dir="RTL">&middot; حمى (سخونة)</p><p dir="RTL">&middot; انخفاض حرارة الجسم</p><p dir="RTL">&middot; اضطراب معدّل السكر (الغلوكوز)</p><p dir="RTL">&middot; اضطراب نتائج اختبارات الوظيفة الكبدية</p><p dir="RTL">&middot; اضطراب أعداد خلايا الدم البيضاء&nbsp;</p><p dir="RTL">&middot; ارتفاع معدل الفلوريد في الدم**</p><p dir="RTL">&middot; هذيان</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>معدل حدوث غير شائع:</strong></p><p dir="RTL">&middot; انخفاض أو ازدياد عدد نوع معين من خلايا الدم البيضاء. قد يترافق تناقص في عدد خلايا الدم البيضاء بالدوخة، التعب، الضعف، تقرحات الفم والميل للإصابة بالعدوى.</p><p dir="RTL">&middot; ارتباك</p><p dir="RTL">&middot; نظم غير طبيعي في القلب</p><p dir="RTL">&middot; انقطاع التنفس</p><p dir="RTL">&middot; كمية غير كافية من الأكسجين</p><p dir="RTL">&middot; الربو</p><p dir="RTL">&middot; صعوبة التبول</p><p dir="RTL">&middot; غلوكوز (سكر) في البول***</p><p dir="RTL">&middot; نتائج غير طبيعية لاختبار الوظيفة الكلوية*</p><p>&nbsp;</p><p dir="RTL"><strong>معدل حدوث غير معروف:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; نوبات، خاصة عند الأطفال</p><p dir="RTL">&middot;&nbsp;&nbsp; حركات نفضان واهتزاز</p><p dir="RTL">&middot;&nbsp;&nbsp; وجود سوائل في الرئتين</p><p dir="RTL">&middot;&nbsp;&nbsp; التهاب الكبد أو تأذّيه. قد يعاني المصابون بمرض الكبد من ألم أو شعور بالامتلاء في البطن، بول داكن، خروج باهت أو أبيض اللون، تعب، حكة عامة، اصفرار العينين، غثيان وتقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp; القصور الكلوي. قد يعاني المصابون بمرض الكلية من شعور بالتعب، تورم أو انتفاخ الوجه، البطن، الفخذين أو الكاحلين، كميات أقل من البول أو مشاكل في التبول وألم في الظهر.</p><p dir="RTL">&middot;&nbsp;&nbsp; اندفاعات جلدية</p><p dir="RTL">&middot;&nbsp;&nbsp; اضطراب نظم القلب (ضربات قلب غير منتظمة أو إيقاع غير طبيعي لضربات القلب) يعرف باسم تطاول الفاصلة QT&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">* إذا أجريت فحصا للدم، فقد يخبرونك بأن هناك تغيرات في الخمائر الكبدية أو الكلوية أو أن هناك مواد أخرى في الدم. هذه لن تسبب في الأحوال العادية أي أعراض.</p><p dir="RTL">** قد ترتفع معدلات الفلوريد في الدم ارتفاعا طفيفا أثناء التخدير أو بعده مباشرة، نتيجة لتفكيك الجسم لـ سيفورين، ولكن لا يعتقد أن هذه المعدلات ضارة وسرعان ما تعود إلى طبيعتها.</p><p dir="RTL">*** إذا أجريت فحصا للبول فقد يخبرونك بوجود الغلوكوز (السكر) في البول. قد لا تظهر لديك أي أعراض.</p><p dir="RTL">ذكرت تقارير نادرة جدا حدوث توقف القلب، وهي حالة يتوقف فيها القلب عن الخفقان. بعد الجراحة، قد يصاب بعض الأطفال بعدم انتظام في ضربات القلب، وهو قد يكون مهددا للحياة، بسبب تغير معدلات البوتاسيوم في الدم.</p><p dir="RTL">الأطفال المصابون بمتلازمة بومبي (Pompe)، وهو مرض يولدون به، قد يعانون من عدم انتظام في ضربات القلب أثناء التخدير بواسطة سيفورين.</p><p dir="RTL"><strong>بعد تلقي سيفورين</strong></p><p dir="RTL">ستعود إلى وعيك أو تستيقظ خلال بضع دقائق. قد يصاب الأطفال على وجه الخصوص بالتململ عند الاستيقاظ.</p><p dir="RTL">أخبر طبيبك أو طبيب التخدير إذا كنت بحاجة لتسكين إضافي للألم.</p><p dir="RTL">إذا ظهرت لديك أي أعراض أخرى غير عادية أو غير متوقعة بعد تلقي سيفوفلوران، أخبر طبيبك في الجناح أو طبيب التخدير على الفور.</p><p dir="RTL">إذا كانت لديك أي أسئلة حول سيفورين لم تجد إجابات لها في هذه النشرة، فاسأل طبيبك في الجناح أو طبيب التخدير.</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا أصبت بأي تأثير جانبي، تحدّث إلى طبيبك. وهذا يشمل أي تأثيرات جانبية غير مدرجة في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن التأثيرات الجانبية يمكنك أيضا المساعدة بتوفير مزيد من المعلومات عن سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن أي تأثير(ات) جانبي(ـة):</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المملكة العربية السعودي</strong><strong>ة</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ والسلامة الدوائية </strong><strong>NPC</strong><strong>&nbsp; </strong></p><p dir="RTL">اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على :</p><p dir="RTL">هاتف: 2038222-11-966+ تحويلة: 2317-2356-2353-2354-2334-2340.</p><p dir="RTL">الهاتف المجاني: 8002490000</p><p dir="RTL">فاكس: +966-11-2057662</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني:&nbsp; www.sfda.gov.sa/npc</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بلدان مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">الرجاء الاتصال بالجهات المختصة المسؤولة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يحفظ سيفورين في عبوة محكمة الإغلاق</p><p dir="RTL">&nbsp;في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">لا يحفظ في الثلاجة</p><p dir="RTL">لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحية المطبوع على العلبة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكوّنات سيفورين:</strong></p><p dir="RTL">المادة الفعالة هي سيفوفلوران. يوجد الماء أيضا لتأمين الحماية لسيفورين من المواد التي قد تسبب تفككه أحماض لويس (Lewis) البيئية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>-</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المعلومات التفصيلية لحامل رخصة التسويق والجهة الصانعة</strong></p><p dir="RTL">حامل رخصة التسويق:</p><p dir="RTL">آبفي ليمتد</p><p dir="RTL">ميدنهيد، المملكة المتحدة</p><p dir="RTL">&nbsp;</p><p><em>&nbsp;</em></p><p dir="RTL">الجهة المصنعة:</p><p dir="RTL">آبفي إس. أر.إل.</p><p dir="RTL">04011، كامبوفيردي دي أبريليا ، إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم آخر تحديث لهذه النشرة في مارس 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sevorane 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The finished product is comprised only of the active ingredient (sevoflurane).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sevorane is a nonflammable volatile liquid. Sevorane is administered via inhalation of the vaporised liquid.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevorane is indicated for induction and maintenance of general anaesthesia in adult and paediatric patients for inpatient and outpatient surgery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Premedication should be selected according to the need of the individual patient, and at the discretion of the anaesthetist.</p><p><strong>Surgical Anaesthesia:</strong></p><p>Sevorane should be delivered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled. MAC (minimum alveolar concentration) values for sevoflurane decrease with age and with the addition of nitrous oxide. The table below indicates average MAC values for different age groups.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p>Table 1: MAC values for Adults and Paediatric patients according to age</p></td></tr><tr><td style="vertical-align:top"><p>Age of Patient (years)</p></td><td style="vertical-align:top"><p>Sevoflurane in Oxygen</p></td><td style="vertical-align:top"><p>Sevoflurane in 65%<br />N2O/35% O2</p></td></tr><tr><td><p>0 &ndash; 1 months*</p></td><td><p>3.3%</p></td><td rowspan="4"><p>2.0%**</p></td></tr><tr><td><p>1 - &lt; 6 months</p></td><td><p>3.0%</p></td></tr><tr><td><p>6 months - &lt; 3 years</p></td><td><p>2.8%</p></td></tr><tr><td><p>3 - 12</p></td><td><p>2.5%</p></td></tr><tr><td><p>25</p></td><td><p>2.6%</p></td><td><p>1.4%</p></td></tr><tr><td><p>40</p></td><td><p>2.1%</p></td><td><p>1.1%</p></td></tr><tr><td><p>60</p></td><td><p>1.7%</p></td><td><p>0.9%</p></td></tr><tr><td><p>80</p></td><td><p>1.4%</p></td><td><p>0.7%</p></td></tr></tbody></table><p>* Neonates are full term gestational age. MAC in premature infants has not</p><p>been determined.</p><p>** In 1 &ndash; &lt;3 year old paediatric patients, 60% N2O/40% O2 was used.</p><p>&nbsp;</p><p><strong>Induction:</strong></p><p>Dosage should be individualised and titrated to the desired effect according to the patient&#39;s age and clinical status. A short acting barbiturate or other intravenous induction agent may be administered followed by inhalation of sevoflurane. Induction with sevoflurane may be achieved in oxygen or in combination with oxygen-nitrous oxide mixtures. In adults inspired concentrations of up to 5% sevoflurane usually produce surgical anaesthesia in less than 2 minutes. In children, inspired concentrations of up to 7% sevoflurane usually produce surgical anaesthesia in less than 2 minutes. Alternatively, for induction of anaesthesia in unpremedicated patients, inspired concentrations of up to 8% sevoflurane may be used.</p><p><strong>Maintenance:</strong></p><p>Surgical levels of anaesthesia may be sustained with concentrations of 0.5 -</p><p>3% sevoflurane with or without the concomitant use of nitrous oxide.</p><p><strong>Emergence:</strong></p><p>Emergence times are generally short following sevoflurane anaesthesia.</p><p>Therefore, patients may require early post-operative pain relief.</p><p><strong>Older people:</strong></p><p>MAC decreases with increasing age. The average concentration of sevoflurane to achieve MAC in an 80 year old is approximately 50% of that required in a 20 year old.</p><p><strong>Paediatric population:</strong></p><p>Refer to Table 1 for MAC values for paediatric patients according to age.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sevoflurane should not be used in patients with known or suspected sensitivity to sevoflurane or other halogenated anaesthetics (e.g. history of liver function disorder, fever or leucocytosis of unknown cause after anaesthesia with one of these agents).
Sevoflurane is also contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia.
Sevoflurane is contraindicated in patients in whom general anaesthesia is contraindicated.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevoflurane may cause respiratory depression, which may be augmented by narcotic premedication or other agents causing respiratory depression. Respiration should be supervised and if necessary, assisted.</p><p>Sevoflurane should be administered only by persons trained in the administration of general anaesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment and circulatory resuscitation must be immediately available.</p><p>The concentration of sevoflurane being delivered from a vaporiser must be known exactly. As volatile anaesthetics differ in their physical properties, only vaporisers specifically calibrated for sevoflurane must be used. The administration of general anaesthesia must be individualised based on the patient&rsquo;s response. Hypotension and respiratory depression increase as anaesthesia is deepened.</p><p><strong>Malignant Hyperthermia</strong></p><p>In susceptible individuals, potent inhalation anaesthetic agents may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia. The clinical syndrome is signalled by hypercapnia, and may include muscle rigidity, tachycardia, tachypnoea, cyanosis, arrhythmias, and/or unstable blood pressure. Some of these nonspecific signs may also appear during light anaesthesia, acute hypoxia, hypercapnia and hypovolaemia.</p><p>In clinical trials, one case of malignant hyperthermia was reported. In addition, there have been postmarketing reports of malignant hyperthermia. Some of these reports have been fatal.</p><p>Treatment includes discontinuation of triggering agents (e.g. sevoflurane), administration of intravenous dantrolene sodium (consult prescribing information for intravenous dantrolene sodium for additional information on patient management), and application of supportive therapy. Such therapy includes vigorous efforts to restore body temperature to normal, respiratory and circulatory support as indicated, and management of electrolyte-fluid-acid-base abnormalities. Renal failure may appear later, and urine flow should be monitored and sustained if possible.</p><p><strong>Perioperative Hyperkalemia</strong></p><p>Use of inhaled anaesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in paediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable. Concomitant use of succinylcholine has been associated with most, but not all, of these cases. These patients also experienced significant elevations in serum creatine kinase levels and, in some cases, changes in urine consistent with myoglobinuria. Despite the similarity in presentation to malignant hyperthermia, none of these patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state. Early and aggressive intervention to treat the hyperkalaemia and resistant arrhythmias is recommended, as is subsequent evaluation for latent neuromuscular disease.</p><p>Isolated reports of QT prolongation, very rarely associated with torsade de pointes (in exceptional cases, fatal), have been received. Caution should be exercised when administering sevoflurane to susceptible patients.</p><p>Isolated cases of ventricular arrhythmia were reported in paediatric patients with Pompe&rsquo;s disease.</p><p>&nbsp;</p><p>Caution should be exercised in administering general anaesthesia, including sevoflurane, to patients with mitochondrial disorders.</p><p><strong>Hepatic</strong></p><p>Very rare cases of mild, moderate and severe post-operative hepatic dysfunction or hepatitis with or without jaundice have been reported from postmarketing experiences.</p><p>Clinical judgment should be exercised when sevoflurane is used in patients with underlying hepatic conditions or under treatment with drugs known to cause hepatic dysfunction (see section 4.8).</p><p>Patients with repeated exposures to halogenated hydrocarbons, including sevoflurane, within a relatively short interval may have an increased risk of hepatic injury.</p><p><strong>General</strong></p><p>During the maintenance of anaesthesia, increasing the concentration of sevoflurane produces dose-dependent decreases in blood pressure. Excessive decrease in blood pressure may be related to depth of anaesthesia and in such instances may be corrected by decreasing the inspired concentration of sevoflurane. Particular care must be taken when selecting the dosage for patients who are hypovolaemic, hypotensive, or otherwise hemodynamically compromised, e.g., due to concomitant medications.</p><p>As with all anaesthetics, maintenance of haemodynamic stability is important to avoid myocardial ischaemia in patients with coronary artery disease.</p><p>Caution should be observed when using sevoflurane during obstetric anaesthesia because the relaxant effect on the uterus could increase the risk of uterine bleeding (see section 4.6).</p><p>The recovery from general anaesthesia should be assessed carefully before patients are discharged from the recovery room. Rapid emergence from anaesthesia is generally seen with sevoflurane so early relief of postoperative pain may be required. Although recovery of consciousness following sevoflurane administration generally occurs within minutes, the impact on intellectual function for two or three days following anaesthesia has not been studied. As with other anaesthetics, small changes in moods may persist for several days following administration (see section 4.7). Rapid emergence in children may be associated with agitation and lack of co-operation (in about 25% of cases).</p><p><strong><em>Replacement of Desiccated CO</em></strong><strong><em>2 </em></strong><strong><em>Absorbents:</em></strong></p><p>Rare cases of extreme heat, smoke, and/or spontaneous fire in the anaesthesia machine have been reported during sevoflurane use in conjunction with the use of desiccated CO2 absorbent, specifically those containing potassium hydroxide (e.g Baralyme). An unusually delayed rise or unexpected decline of inspired sevoflurane concentration compared to the vaporiser setting may be associated with excessive heating of the CO2 absorbent canister.</p><p>An exothermic reaction, enhanced sevoflurane degradation, and production of degradation products can occur when the CO2 absorbent becomes desiccated, such as after an extended period of dry gas flow through the CO2 absorbent canisters. Sevoflurane degradants (methanol, formaldehyde, carbon monoxide, and Compounds A, B, C, and D) were observed in the respiratory circuit of an experimental anaesthesia machine using desiccated CO2 absorbents and maximum sevoflurane concentrations (8%) for extended periods of time (&ge; 2 hours). Concentrations of formaldehyde observed at the anaesthesia respiratory circuit (using sodium hydroxide containing absorbents) were consistent with levels known to cause mild respiratory irritation. The clinical relevance of the degradants observed under this extreme experimental model is unknown.</p><p>If a health care professional suspects that the CO2 absorbent has become desiccated, it must be replaced before subsequent use of volatile anaesthetics (such as sevoflurane). It must be taken into account that the colour indicator does not always change after desiccation has taken place. Therefore, the lack of significant colour change should not be taken as an assurance of adequate hydration. CO2 absorbents should be replaced routinely regardless of the state of the colour indicator.</p><p><strong>Renal Impairment:</strong></p><p>Because of the small number of patients with renal insufficiency (baseline serum creatinine greater than 1.5mg/dL) studied, the safety of sevoflurane administration in this group has not been fully established. Therefore, sevoflurane should be used with caution in patients with renal insufficiency.</p><p>In some studies in rats, nephrotoxicity was seen in animals exposed to levels of Compound A (pentafluoroisopropenyl fluoromethyl ether (PIFE)) in excess of those usually seen in routine clinical practice. The mechanism of this renal toxicity in rats is unknown and its relevance to man has not been established. (See Section 5.3, Preclinical Safety Data for further details.)</p><p><strong>Neurosurgery &amp; Neuromuscular Impairment:</strong></p><p>In patients at risk from elevation of intra-cranial pressure, sevoflurane should be administered cautiously in conjunction with techniques to lower intra-cranial pressure (e.g. hyperventilation).</p><p><strong>Seizures:</strong></p><p>Rare cases of seizures have been reported in association with sevoflurane use.</p><p>Use of sevoflurane has been associated with seizures occurring in children and young adults as well as older adults with and without predisposing risk factors. Clinical judgment is necessary before sevoflurane is used in patients at risk of seizures. In children the depth of anaesthesia should be limited. EEG may permit the optimization of sevoflurane dose and help avoid the development of seizure activity in patients with a predisposition for seizures (see section 4.4-Paediatric population).</p><p><strong>Paediatric population:</strong></p><p>The use of sevoflurane has been associated with seizures. Many have occurred in children and young adults starting from 2 months of age, most of whom had no predisposing risk factors. Clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures (see section 4.4 &ndash; Seizures).</p><p>Dystonic movements in children have been observed (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Beta-sympathomimetic agents like isoprenaline and alpha- and beta-sympathomimetic agents like adrenaline and noradrenaline should be used with caution during Sevoflurane narcosis, due to a potential risk of ventricular arrhythmia.</p><p>Non-selective MAO-inhibitors: Risk of crisis during the operation. It is generally recommended that treatment should be stopped 2 weeks prior to surgery.</p><p>Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists, in particular dihydropyridine derivates.</p><p>Caution should be exercised when calcium antagonists are used concomitantly with inhalation anesthetics due to the risk of additive negative inotropic effect.</p><p>Concomitant use of succinylcholine with inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the post-operative period.</p><p>Sevoflurane has been shown to be safe and effective when administered concurrently with a wide variety of agents commonly encountered in surgical situations such as central nervous system agents, autonomic drugs, skeletal muscle relaxants, anti-infective agents including aminoglycosides, hormones and synthetic substitutes, blood derivatives and cardiovascular drugs, including epinephrine.</p><p><em>Epinephrine/Adrenaline</em></p><p>Sevoflurane is similar to isoflurane in the sensitisation of the myocardium to</p><p>the arrhythmogenic effect of exogenously administered adrenaline.</p><p><em>Indirect-acting Sympathomimetics</em></p><p>There is a risk of acute hypertensive episode with the concomitant use of sevoflurane and indirect-acting sympathomimetics products (amphetamines, ephedrine).</p><p>&nbsp;</p><p><em>Beta blockers</em></p><p>Sevoflurane may increase the negative inotropic, chronotropic and dromotropic effects of beta blockers (by blocking cardiovascular compensatory mechanisms).</p><p><em>Verapamil</em></p><p>Impairment of atrioventricular conduction was observed when verapamil and</p><p>sevoflurane were administered at the same time.</p><p><em>Inducers of CYP2E1</em></p><p>Medicinal products and compounds that increase the activity of cytochrome P450 isoenzyme CYP2E1, such as isoniazid and alcohol, may increase the metabolism of sevoflurane and lead to significant increases in plasma fluoride concentrations. Concomitant use of sevoflurane and isoniazid can potentiate the hepatotoxic effects of isoniazid.</p><p><em>St John&rsquo;s Wort</em></p><p>Severe hypotension and delayed emergence from anaesthesia with halogenated inhalational anaesthetics have been reported in patients treated long-term with St John&rsquo;s Wort.</p><p><em>Barbiturates</em></p><p>Sevoflurane administration is compatible with barbiturates as commonly used in surgical practice.</p><p><em>Benzodiazepines and Opioids</em></p><p>Benzodiazepines and opioids are expected to decrease the MAC of sevoflurane in the same manner as with other inhalational anaesthetics. Sevoflurane administration is compatible with benzodiazepines and opioids as commonly used in surgical practice.</p><p>Opioids such as alfentanil and sufentanil, when combined with sevoflurane, may lead to a synergistic fall in heart rate, blood pressure and respiratory rate.</p><p><em>Nitrous Oxide</em></p><p>As with other halogenated volatile anaesthetics, the MAC of sevoflurane is decreased when administered in combination with nitrous oxide. The MAC equivalent is reduced approximately 50% in adult and approximately 25% in paediatric patients (see section 4.2 &ndash; Maintenance).</p><p><em>Neuromuscular Blocking Agents</em></p><p>As with other inhalational anaesthetic agents, sevoflurane affects both the intensity and duration of neuromuscular blockade by non-depolarising muscle relaxants. When used to supplement alfentanil-N2O anaesthesia, sevoflurane potentiates neuromuscular block induced with pancuronium, vecuronium or atracurium. The dosage adjustments for these muscle relaxants when administered with sevoflurane are similar to those required with isoflurane. The effect of sevoflurane on succinylcholine and the duration of depolarising neuromuscular blockade has not been studied.</p><p>&nbsp;</p><p>Dosage reduction of neuromuscular blocking agents during induction of anaesthesia may result in delayed onset of conditions suitable for endotracheal intubation or inadequate muscle relaxation because potentiation of neuromuscular blocking agents is observed a few minutes after the beginning of sevoflurane administration.</p><p>Among non-depolarising agents, vecuronium, pancuronium and atracurium interactions have been studied. In the absence of specific guidelines: (1) for endotracheal intubation, do not reduce the dose of non-depolarising muscle relaxants; and, (2) during maintenance of anaesthesia, the dose of non-depolarising muscle relaxants is likely to be reduced compared to that during N2O/opioid anaesthesia. Administration of supplemental doses of muscle relaxants should be guided by the response to nerve stimulation.</p><p>As with other agents, lesser concentrations of sevoflurane may be required following use of an intravenous anaesthetic e.g. propofol.</p><p>Significant increases in plasma fluoride concentrations have been observed following the increased activity of CYP 2E1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pregnancy</em></strong></p><p>Sevoflurane has a relaxant effect on the uterus, which can lead to increased uterine bleeding, as was reported in a study of its use during termination of pregnancy. Use during labour and delivery is limited to one small study in caesarean section.</p><p>In animal reproduction studies, reduced foetal weights were noted following exposure to 1 MAC sevoflurane for three hours a day during organogenesis (see section 5.3). There are no adequate and well-controlled studies in pregnant women; therefore, sevoflurane should be used during pregnancy only if clearly needed.</p><p><strong><em>Labour and Delivery</em></strong></p><p>In a clinical trial, the safety of sevoflurane was demonstrated for mothers and infants when used for anaesthesia during Caesarean section. The safety of sevoflurane in labour and vaginal delivery has not been demonstrated.</p><p><strong><em>Breastfeeding</em></strong></p><p>It is not known whether sevoflurane or its metabolites are excreted in human milk. Due to the absence of documented experience, women should be advised to skip breast-feeding for 48 hours after administration of sevoflurane and discard milk produced during this period.</p><p><strong><em>Fertility</em></strong></p><p>A fertility study in rats has revealed no evidence of impaired fertility due to sevoflurane (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other agents, patients should be advised that performance of activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, may be impaired for some time after general anaesthesia (see section 4.4).</p><p>Patients should not be allowed to drive for a suitable period after sevoflurane anaesthesia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p>As with all potent inhaled anaesthetics, sevoflurane may cause dose-dependent cardio-respiratory depression. Most adverse reactions are mild to moderate in severity and are transient in duration. Nausea, vomiting and delirium are commonly observed in the post-operative period, at a similar incidence to those found with other inhalation anaesthetics. These effects are common sequelae of surgery and general anaesthesia which may be due to the inhalational anaesthetic, other agents administered intra-operatively or post&shy;operatively and to the patient&#39;s response to the surgical procedure.</p><p>The most commonly reported adverse reactions were as follows:</p><p>In adult patients: hypotension, nausea and vomiting;</p><p>In elderly patients: bradycardia, hypotension and nausea; and</p><p>In paediatric patients: agitation, cough, vomiting and nausea.</p><p><strong>Tabulated summary of adverse reactions</strong></p><p>All adverse reactions at least possibly relating to sevoflurane from clinical trials and post-marketing experience are presented in the following table by MedDRA System Organ Class, Preferred Term and frequency. The following frequency categories are used: Very common (&gt;1/10); common (&gt;1/100, &lt;1/10); uncommon (&gt;1/1,000, &lt;1/100); rare (&gt;1/10,000, &lt;1/1,000); very rare (&lt;1/10,000), including isolated reports. Post-marketing adverse reactions are reported voluntarily from a population with an unknown rate of exposure. Therefore it is not possible to estimate the true incidence of adverse events and the frequency is &ldquo;unknown&rdquo;. The type, severity and frequency of adverse reactions in sevoflurane patients in clinical trials were comparable to adverse reactions in reference-drug patients.</p><p><strong>Adverse Reaction Data Derived From Clinical Trials and Post-marketing Experience</strong></p><p><strong>Summary of Most Frequent Adverse Drug Reactions <u>in sevoflurane Clinical Trials and Post-marketing Experience</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:546px"><tbody><tr><td><p><strong><em><u>System Organ Class</u></em></strong></p></td><td><p><strong><em><u>Frequency</u></em></strong></p></td><td><p><strong><em>Adverse Reactions</em></strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:546px"><tbody><tr><td style="vertical-align:top; width:212px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:133px"><p>Unknown</p></td><td style="vertical-align:top; width:199px"><p>Anaphylactic reaction 1 Anaphylactoid reaction Hypersensitivity 1</p></td></tr><tr><td style="vertical-align:top; width:212px"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:133px"><p>Uncommon</p></td><td style="vertical-align:top; width:199px"><p>Leukopenia<br />Leukocytosis</p></td></tr><tr><td style="vertical-align:top; width:212px"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:133px"><p>Very Common Uncommon</p></td><td style="vertical-align:top; width:199px"><p>Agitation</p><p>Confusional state</p></td></tr><tr><td style="vertical-align:top; width:212px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:133px"><p>Common</p><p>Unknown</p></td><td style="vertical-align:top; width:199px"><p>Somnolence<br />Dizziness<br />Headache</p><p>Convulsion 2, 3<br />Dystonia</p></td></tr><tr><td style="vertical-align:top; width:212px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:133px"><p>Very Common Common Uncommon</p><p>Unknown</p></td><td style="vertical-align:top; width:199px"><p>Bradycardia<br />Tachycardia</p><p>Atrioventricular block complete Atrial fibrillation</p><p>Arrythmia</p><p>Ventricular extrasystoles Supraventricular extrasystoles Extrasystoles</p><p>Cardiac arrest 4</p><p>QT prolongation associated with</p><p>Torsade</p></td></tr><tr><td style="vertical-align:top; width:212px"><p>Vascular disorders</p></td><td style="vertical-align:top; width:133px"><p>Very Common Common</p></td><td style="vertical-align:top; width:199px"><p>Hypotension<br />Hypertension</p></td></tr><tr><td style="vertical-align:top; width:212px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:133px"><p>Very Common</p><p>Common</p><p>Uncommon</p><p>Unknown</p></td><td style="vertical-align:top; width:199px"><p>Cough</p><p>Respiratory disorder Laryngospasm</p><p>Apnoea<br />Hypoxia<br />Asthma</p><p>Bronchospasm<br />Dyspnoea 1<br />Wheezing 1<br />Pulmonary oedema</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:551px"><tbody><tr><td style="vertical-align:top; width:227px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:117px"><p>Very Common</p><p>Common</p></td><td style="vertical-align:top; width:205px"><p>Nausea<br />Vomiting</p><p>Salivary hypersecretion</p></td></tr><tr><td style="vertical-align:top; width:227px"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:117px"><p>Uncommon</p><p>Unknown</p></td><td style="vertical-align:top; width:205px"><p>Urinary retention<br />Glycosuria</p><p>Renal failure acute</p></td></tr><tr><td style="vertical-align:top; width:227px"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top; width:117px"><p>Unknown</p></td><td style="vertical-align:top; width:205px"><p>Hepatitis 1, 2</p><p>Hepatic failure 1, 2<br />Hepatic necrosis 1, 2</p></td></tr><tr><td style="vertical-align:top; width:227px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:117px"><p>Unknown</p></td><td style="vertical-align:top; width:205px"><p>Dermatitis contact 1</p><p>Pruritus</p><p>Rash 1</p><p>Swelling face 1</p><p>Urticaria</p></td></tr><tr><td style="vertical-align:top; width:227px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:117px"><p>Unknown</p></td><td style="vertical-align:top; width:205px"><p>Muscle twitching</p></td></tr><tr><td style="vertical-align:top; width:227px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:117px"><p>Common</p><p>Unknown</p></td><td style="vertical-align:top; width:205px"><p>Chills<br />Pyrexia</p><p>Hypothermia</p><p>Chest discomfort 1</p><p>Hyperthermia malignant 1, 2</p></td></tr><tr><td style="vertical-align:top; width:227px"><p>Investigations</p></td><td style="vertical-align:top; width:117px"><p>Common</p><p>Uncommon</p></td><td style="vertical-align:top; width:205px"><p>Blood glucose abnormal Liver function test abnormal 5 White blood cell count abnormal Aspartate aminotransferase increased</p><p>Blood fluoride increased<sup>6</sup></p><p>Alanine aminotransferase increased</p><p>Blood creatinine increased Blood lactate dehydrogenase increased</p></td></tr><tr><td style="vertical-align:top; width:227px"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top; width:117px"><p>Common</p></td><td style="vertical-align:top; width:205px"><p>Hypothermia</p></td></tr></tbody></table><p>&nbsp;</p><p>1 See section 4.8 &ndash; Description of selected adverse reactions.</p><p>2 See section 4.4.</p><p>3 See section 4.8 &ndash; Paediatric population.</p><p>4 There have been very rare post-marketing reports of cardiac arrest in the setting of sevoflurane use.</p><p>&nbsp;</p><p>5 Occasional cases of transient changes in hepatic function tests were reported with sevoflurane and reference agents.</p><p>6 Transient increases in serum inorganic fluoride levels may occur during and after sevoflurane anaesthesia. See <strong>Description of selected adverse reactions </strong>below.</p><p><strong>Description of selected adverse reactions</strong></p><p>Transient increases in serum inorganic fluoride levels may occur during and after sevoflurane anaesthesia. Concentrations of inorganic fluoride generally peak within two hours of the end of sevoflurane anaesthesia and return within 48 hours to pre-operative levels. In clinical trials, elevated fluoride concentrations were not associated with impairment of renal function.</p><p>Rare reports of post-operative hepatitis exist. In addition, there have been rare post-marketing reports of hepatic failure and hepatic necrosis associated with the use of potent volatile anaesthetic agents, including sevoflurane. However, the actual incidence and relationship of sevoflurane to these events cannot be established with certainty (see section 4.4).</p><p>Rare reports of hypersensitivity (including contact dermatitis, rash, dyspnoea, wheezing, chest discomfort, swelling face, or anaphylactic reaction) have been received, particularly in association with long-term occupational exposure to inhaled anaesthetic agents, including sevoflurane.</p><p>In susceptible individuals, potent inhalation anaesthetic agents may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia (see section 4.4).</p><p><strong>Paediatric population</strong></p><p>The use of sevoflurane has been associated with seizures. Many of these have occurred in children and young adults starting from 2 months of age, most of whom had no predisposing risk factors. Clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures (see section 4.4).</p><p>Reporting of suspected adverse reactions</p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via The National Pharmacovigilance and Drug Safety Centre (NPC):</p><p>&nbsp;</p><p><strong>Saudi Arabia</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p><strong>&nbsp;</strong></p><p><strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdosage, the following action should be taken: Stop drug</p><p>administration, establish a clear airway and initiate assisted or controlled ventilation with pure oxygen and maintain adequate cardiovascular function.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmaco-therapeutic group: Anaesthetics, general - ATC code: N01A</p><p>Changes in the clinical effects of sevoflurane rapidly follow changes in the</p><p>inspired concentration.</p><p>&nbsp;</p><p><u>Cardiovascular Effects</u></p><p>As with all other inhalation agents sevoflurane depresses cardiovascular</p><p>function in a dose related fashion. In one volunteer study, increases in</p><p>sevoflurane concentration resulted in decrease in mean arterial pressure, but</p><p>there was no change in heart rate. Sevoflurane did not alter plasma</p><p>noradrenaline concentrations in this study.</p><p>&nbsp;</p><p><u>Nervous System Effects</u></p><p>No evidence of seizure was observed during the clinical development programme.</p><p>&nbsp;</p><p>In patients with normal intracranial pressure (ICP), sevoflurane had minimal</p><p>effect on ICP and preserved CO 2 responsiveness. The safety of sevoflurane</p><p>has not been investigated in patients with a raised ICP. In patients at risk for</p><p>elevations of ICP, sevoflurane should be administered cautiously in</p><p>conjunction with ICP-reducing manoeuvres such as hyperventilation.</p><p>&nbsp;</p><p><u>Paediatric</u></p><p>Some published studies in children have observed cognitive deficits after</p><p>repeated or prolonged exposures to anaesthetic agents early in life. These</p><p>studies have substantial limitations, and it is not clear if the observed effects</p><p>are due to the anaesthetic/sedation drug administration or other factors such as</p><p>the surgery or underlying illness. In addition, more recent published registry</p><p>studies did not confirm these findings.</p><p>Published animal studies of some anaesthetic/sedation drugs have reported</p><p>adverse effects on brain development in early life (see section 5.3 &ndash; Preclinical</p><p>safety data).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The low solubility of sevoflurane in blood should result in alveolar concentrations which rapidly increase upon induction and rapidly decrease upon cessation of the inhaled agent.</p><p>In humans &lt;5% of the absorbed sevoflurane is metabolised. The rapid and extensive pulmonary elimination of sevoflurane minimises the amount of anaesthetic available for metabolism. Sevoflurane is defluorinated via cytochrome p450(CYP)2E1 resulting in the production of hexafluoroisopropanol (HFIP) with release of inorganic fluoride and carbon dioxide (or a one carbon fragment). HFIP is then rapidly conjugated with glucuronic acid and excreted in the urine.</p><p>The metabolism of sevoflurane may be increased by known inducers of CYP2E1 (e.g. isoniazid and alcohol), but it is not inducible by barbiturates.</p><p>Transient increases in serum inorganic fluoride levels may occur during and after sevoflurane anaesthesia. Generally, concentrations of inorganic fluoride peak within 2 hours of the end of sevoflurane anaesthesia and return within 48 hours to pre-operative levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies have shown that hepatic and renal circulation are well maintained with sevoflurane.</p><p>&nbsp;</p><p>Sevoflurane decreases the cerebral metabolic rate for oxygen (CMRO2 ) in a fashion analogous to that seen with isoflurane. An approximately 50% reduction of CMRO2 is observed at concentrations approaching 2.0 MAC.</p><p>Animal studies have demonstrated that sevoflurane does not have a significant effect on cerebral blood flow.</p><p>In animals, sevoflurane significantly suppresses electroencephalographic (EEG) activity comparable to equipotent doses of isoflurane. There is no evidence that sevoflurane is associated with epileptiform activity during normocapnia or hypocapnia. In contrast to enflurane, attempts to elicit seizure-like EEG activity during hypocapnia with rhythmic auditory stimuli have been negative.</p><p>Compound A was minimally nephrotoxic at concentrations of 50-114 ppm for 3 hours in a range of studies in rats. The toxicity was characterised by sporadic single cell necrosis of the proximal tubule cells. The mechanism of this renal toxicity in rats is unknown and its relevance to man has not been established. Comparable human thresholds for Compound A-related nephrotoxicity would be predicted to be 150-200 ppm. The concentrations of Compound A found in routine clinical practice are on average 19 ppm in adults (maximum 32 ppm) with use of Soda lime as the CO2 absorbent.</p><p>Developmental toxicity studies have been performed in pregnant rats and rabbits at doses up to 1 MAC for three hours per day. Reduced foetal body weights concomitant with increased skeletal variations were noted in rats only at maternally toxic concentrations. No adverse foetal effects were observed in rabbits. In fertility studies in rats at doses up to 1 MAC no effects on male and female reproductive capabilities were observed.</p><p>Published studies in pregnant and juvenile animals suggest that the use of anaesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity during the period of rapid brain growth or synaptogenesis may result in neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis when used for longer than 3 hours. These studies included anaesthetic agents from a variety of drug classes. The clinical significance of these nonclinical findings is yet to be determined (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Water (as a Lewis Acid Inhibitor).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevorane is stable when stored under normal room lighting conditions. No discernible degradation of sevoflurane occurs in the presence of strong acids or heat. Sevoflurane is not corrosive to stainless steel, brass, aluminum nickel-plated brass, chrome-plated brass or copper beryllium alloy.</p><p>Chemical degradation can occur upon exposure of inhaled anaesthetics to CO2 absorbent within the anaesthesia machine. When used as directed with fresh absorbents, degradation of sevoflurane is minimal and degradants are undetectable or non-toxic. Sevoflurane degradation and subsequent degradant formation are enhanced by increasing absorbent temperature, desiccated CO2 absorbent (especially potassium hydroxide-containing, e.g. Baralyme<sup>&reg;</sup>), increased sevoflurane concentration and decreased fresh gas flow. Sevoflurane can undergo alkaline degradation by two pathways. The first results from the loss of hydrogen fluoride with the formation of pentafluoroisopropanyl fluoromethyl ether (PIFE or more commonly known as Compound A). The second pathway for degradation of sevoflurane occurs only in the presence of desiccated CO2 absorbents and leads to the dissociation of sevoflurane into hexafluoroisopropanol (HFIP) and formaldehyde. HFIP is inactive, non-genotoxic, rapidly glucoronidated, cleared and has toxicity comparable to sevoflurane. Formaldehyde is present during normal metabolic processes. Upon exposure to a highly desiccated absorbent, formaldehyde can further degrade into methanol and formate. Formate can contribute to the formation of carbon monoxide in the presence of high temperature. Methanol can react with compound A to form the methoxy addition product Compound B. Compound B can undergo further HF elimination to form Compounds C,D and E. With highly desiccated absorbents, especially those containing potassium hydroxide (e.g Baralyme<sup>&reg;</sup>) the fomation of formaldehyde, methanol, carbon monoxide, Compound A and perhaps some of its degradants, Compounds B,C and D may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The recommended shelf life is 36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Do not refrigerate. Keep cap tightly closed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>100ml and 250ml amber polyethylene napthalate (PEN) bottles. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevorane should be administered via a vaporiser calibrated specifically for sevoflurane using a key filling system designed for sevoflurane specific vaporisers or other appropriate sevoflurane specific vaporiser filling systems. Carbon dioxide absorbents should not be allowed to dry out when inhalational anaesthetics are being administered. Some halogenated anaesthetics have been reported to interact with dry carbon dioxide absorbent to form carbon monoxide. However, in order to minimise the risk of formation of carbon monoxide in re-breathing circuits and the possibility of elevated carboxyhaemoglobin levels, CO2 absorbents should not be allowed to dry out. There have been rare cases of excessive heat production, smoke and fire in the anaesthetic machine when sevoflurane has been used in conjunction with a desiccated (dried out) CO2 absorbent. If the CO2 absorbent is suspected to be desiccated it should be replaced.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 AbbVie Ltd.,
Maidenhead,
 United Kingdom


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                             1 March 2018.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>